Humanin

What it is

Humanin is a mitochondrial-derived peptide first reported by Hashimoto and colleagues in 2001 during work on neuronal survival in models related to Alzheimer disease^{[5 –6 ]}. The original paper described a factor that protected neuronal cells from cell death induced by familial Alzheimer disease-associated genes and amyloid beta toxicity^{[5 ]}. This discovery helped establish the concept that short open reading frames in mitochondrial DNA could encode biologically active peptides with signaling roles outside the mitochondrion^{[5 –6 ]}.

Mechanistically, humanin is not a single-pathway molecule. Early research linked it to anti-apoptotic activity and cell-survival pathways^{[5 –6 ]}. Later work reported interactions with insulin-like growth factor-binding protein 3, or IGFBP-3, which can regulate apoptosis and cell survival^{[7 ]}. Other studies have investigated cell-surface receptor signaling, intracellular interactions with pro-apoptotic proteins, metabolic effects, and inflammatory resolution biology^{[7 –12 ]}.

Humanin is frequently discussed in longevity and mitochondrial-health circles because mitochondrial function changes with aging and because some preclinical studies connect humanin biology to stress resistance, insulin action, and neurodegenerative models^{[8 –11 ]}. Those hypotheses remain early-stage. Humanin is not an FDA-approved drug for aging, fatigue, cognition, diabetes, Alzheimer disease, cardiovascular disease, or mitochondrial disease.

Administration in published work varies widely because most research is cellular, animal, or biomarker-based rather than clinical. Humanin analogs such as S14G-humanin have been administered experimentally in animal models^{[8 –9 ]}. This page describes published research and regulatory status only and does not provide dosing, route, or protocol guidance.

Regulatory status

No FDA-approved humanin product was identified for this draft. Humanin is not approved in the United States for Alzheimer disease, cognitive impairment, metabolic disease, mitochondrial dysfunction, anti-aging, fatigue, or any other indication.

Under FDA’s 503A framework, state-licensed pharmacies and physicians compounding from bulk substances must use substances that meet an applicable USP/NF monograph pathway, are components of FDA-approved drug products when no monograph exists, or appear on the 503A bulks list^{[1 ]}. Humanin was not identified on the April 22, 2026 503A category list reviewed for this draft^{[2 ]}.

Under FDA’s 503B framework, outsourcing facilities generally may not use a bulk drug substance unless it is on the 503B bulks list or the drug appears on FDA’s shortage list at the time of compounding, distribution, and dispensing^{[3 ]}. No 503B pathway for humanin was identified in the FDA sources reviewed^{[3 ]}.

Humanin is not listed in federal controlled-substance schedules in 21 CFR Part 1308 as reviewed on May 7, 2026^{[4 ]}. That does not imply FDA approval, lawful compounding, or product quality.

Date of last regulatory verification: May 7, 2026. Because humanin is often sold online as a research chemical, any claim of US clinical availability should be checked carefully against FDA approval, compounding, pharmacy, and state medical-practice rules before publication.

Research summary

The foundational research is preclinical and mechanistic. Hashimoto and colleagues first described humanin as a rescue factor that protected neuronal cells from cell death caused by familial Alzheimer disease genes and amyloid beta^{[5 ]}. A companion mechanistic paper investigated how humanin protected against toxicity from Swedish mutant amyloid precursor protein in cell models^{[6 ]}. These papers support biological plausibility, not clinical efficacy in humans.

IGFBP-3 and apoptosis biology

Humanin’s cell-survival biology expanded beyond Alzheimer disease models. Ikonen and colleagues reported that humanin interacts with IGFBP-3 and regulates cell survival and apoptosis^{[7 ]}. This is relevant because IGFBP-3 is involved in growth-factor biology, apoptosis, and cancer-related pathways; however, it does not establish whether humanin is beneficial or harmful in any human disease state.

Metabolic and Alzheimer disease research

Metabolic research is also mostly preclinical. Muzumdar and colleagues reported that humanin acted as a central regulator of peripheral insulin action in animal models^{[8 ]}. These findings are often cited in metabolic and longevity discussions, but they do not establish human treatment effects for diabetes, insulin resistance, obesity, or metabolic syndrome.

Neurodegeneration research includes analog studies such as S14G-humanin. Zhang and colleagues reported that S14G-humanin improved cognitive deficits and reduced amyloid pathology in APPswe/PS1dE9 mice^{[9 ]}. That model is useful for mechanistic research but has limited ability to predict human Alzheimer disease outcomes. No large randomized human trial of humanin for Alzheimer disease was identified as of May 7, 2026.

Aging and longevity-variant research

Aging and genetics research remains exploratory. Miller and colleagues reported that a humanin variant, P3S, was associated with longevity in APOE4 carriers and resisted APOE4-induced brain pathology in experimental models^{[10 ]}. Such work is important for hypothesis generation but should not be translated into claims that administered humanin extends human lifespan or prevents dementia.

Safety signals

Safety-related research is incomplete and includes cautionary signals. Ha and colleagues reported that humanin activated an integrin alphaV-TGF beta axis and promoted glioblastoma progression in experimental work^{[11 ]}. Separately, observational work in chronic hemodialysis patients found altered circulating humanin levels associated with cardiovascular risk, but biomarker association is not evidence that supplementation improves outcomes^{[12 ]}. Overall, the research base is broad but mostly nonclinical, and human therapeutic evidence is not established.

Endogenous biology vs. administered therapy

The most important interpretive point is that endogenous humanin biology and administered humanin therapy are not the same question. A study showing that humanin is associated with a disease state, stress response, or longevity-linked genotype can support biological relevance^{[10 ,12 ]}. It does not show that injecting or ingesting humanin changes clinical outcomes in the intended direction.

Humanin’s apparent cytoprotective role also cuts both ways. Protection from apoptosis may be desirable in neurons exposed to toxic stress in a cell model^{[5 –6 ]}, but the same broad survival biology could be undesirable in malignancy or premalignant tissue^{[11 ]}. This is why the evidence should be framed as mitochondrial-derived peptide research rather than as a generalized anti-aging or neuroprotective intervention.

No published large randomized clinical trials were identified for Alzheimer disease, diabetes, kidney disease, cardiovascular disease, cancer prevention, fatigue, or longevity. As of May 7, 2026, claims in those areas should be described as mechanistic, animal, biomarker, or speculative unless tied to a specific cited human study.

Public discourse

No qualifying public-discourse entries were identified for this page. Search results included research articles, longevity commentary, marketing pages, and anonymous forum posts, but no accessible named-source podcast, article, or transcript with a verifiable quote meeting this site’s citation standard.

Public discourse reflects the views of the speakers cited and does not represent medical advice or the editorial position of ProPeptideGuide.

Side effects and safety

There is no FDA-approved humanin label, so there is no FDA-reviewed adverse-reaction table, contraindication list, drug-interaction section, or pregnancy/lactation guidance. This is a major limitation for any clinical claim.

Theoretical concerns

Theoretical concerns follow from humanin’s biology. A peptide that influences apoptosis, cell survival, inflammation, insulin signaling, and growth-factor-binding pathways could plausibly have different effects depending on tissue type, disease state, dose, route, and exposure duration^{[7 –8 ,11 ]}. The glioblastoma progression paper is particularly important because it shows that a broadly “cell-protective” mechanism can be undesirable in a cancer context^{[11 ]}.

Long-term human safety unknown

Long-term human safety data are not available. Biomarker studies of endogenous circulating humanin are not the same as interventional studies of administered humanin or synthetic analogs^{[12 ]}. Safety cannot be inferred from mitochondrial origin or from animal-model benefit.

Grey-market product risks

Grey-market humanin products create additional concerns about identity, sterility, purity, endotoxin content, aggregation, labeling accuracy, and storage stability. None of these concerns is resolved by the presence of preclinical publications.

Humanin analogs add another layer of uncertainty. S14G-humanin has been used in animal research and may have different potency or pharmacology from native humanin^{[9 ]}. Evidence for one analog should not be treated as interchangeable with evidence for another analog, compounded product, or vendor-labeled research chemical.

Available through

Humanin is not currently available through FDA-compliant channels in the United States as of 2026-05-07^{[1 –3 ]}. ProPeptideGuide does not link to or endorse grey-market vendors.